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Background: Numerous scientific organisations have developed evidence-based recommendations
aiming to optimise the management of osteoarthritis (OA). Uptake, however, has been suboptimal. The
purpose of this exercise was to harmonize the recent recommendations and develop a user-friendly
treatment algorithm to facilitate translation of evidence into practice.
Methods: We updated a previous systematic review on clinical practice guidelines (CPGs) for OA man-
agement. The guidelines were assessed using the Appraisal of Guidelines for Research and Evaluation for
quality and the standards for developing trustworthy CPGs as established by the National Academy of
Medicine (NAM). Four case scenarios and algorithms were developed by consensus of a multidisciplinary
panel.
Results: Sixteen guidelines were included in the systematic review. Most recommendations were
directed toward physicians and allied health professionals, and most had multi-disciplinary input.
Analysis for trustworthiness suggests that many guidelines still present a lack of transparency. A treat-
ment algorithm was developed for each case scenario advised by recommendations from guidelines and
based on panel consensus.
Conclusion: Strategies to facilitate the implementation of guidelines in clinical practice are necessary. The
algorithms proposed are examples of how to apply recommendations in the clinical context, helping the
clinician to visualise the patient flow and timing of different treatment modalities.
© 2016 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.S.R.F. Meneses, Royal North Shore Hospital, Rheumatology Department, Clinical Administration, 7C, Level 7, Reserve
eses).
ternational. Published by Elsevier Ltd. All rights reserved.
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In recent years the American College of Rheumatology (ACR)1,
Osteoarthritis Research Society International (OARSI)2, American
Academy of Orthopaedic Surgeons (AAOS)3, National Institute for
Health and Care Excellence (NICE)4, European League against
Rheumatism (EULAR)5 and others have developed recommenda-
tions through Clinical Practice Guidelines (CPGs) to optimise the
treatment of hand, hip and/or knee osteoarthritis (OA) based on a
variable combination of expert consensus and systematic review of
clinical research evidence. These guidelines have many common-
alities, however, uptake has been suboptimal6,7.
A task force led by the US Chronic Osteoarthritis Management
Initiative (COAMI) Work Group of the US Bone and Joint Initiative
examined the potential issues and barriers involved in the trans-
lation of CPGs to clinical practice8. The authors found that infor-
mation about guideline applicability such as items regarding
facilitators and barriers to guideline use, practical advice concern-
ing guideline implementation, resource implications and moni-
toring/auditing criteria was often not included. A critical review of
guidelines published in 2007 stated that in order to improve
applicability and to increase uptake by end users, stakeholder
opinions and barriers to use need to be taken into account during
guideline development9. Furthermore, effective delivery of treat-
ments requires clear procedural details of the essential elements of
treatment, including howandwhen they are best administered, but
unfortunately, these details are often lacking10.
A general practitioner survey of adherence to EULAR 2000 rec-
ommendations found that the majority of the physicians were
aware of OA guidelines (79%) and almost all of them agreed with
the recommendations (97%), but only 54% adhered to the phar-
macological and non-pharmacological recommendations11. These
findings suggest a deficiency of methods to operationalize and
disseminate the existing recommendations in target populations
across specialties, particularly in general practice. With this insight,
the 2014 version of the NICE guideline offered implementation
tools and resources to help users put the recommendations into
practice; hopefully this advancement will be adopted in future
guidelines4. The current study offers a different view, as we based
our strategy on examples of clinical scenarios in order to bring the
recommendations to the reality of clinical practice.
The purposes of this exercise were: (i) to harmonize the recent
guidelines, searching for common ground among the recom-
mended treatment options for OA and (ii) to develop user-friendly
management algorithms for common case scenarios as a method
to discuss, prioritise and put into a complex setting/context the
different individual recommendations, aiming to facilitate the
translation of evidence-based recommendations into practice. The
target audience is professionals across countries involved with the
primary care of OA but also relevant to secondary care professionals.Materials and methods
To accomplish our research objectives we coordinated the ex-
ercise in five distinct phases:
(1) Participants e invitation of health professionals in the field of
OA (OA panel and systematic review panel, described below)
and two people living with symptoms of knee OA (public
involvement);
(2) Systematic review updatee update of the appraisal of existing
guidelines8;
(3) Trustworthy guidelines assessment e assessment of selected
guidelines according to the standards for developingtrustworthy CPGs as established by the National Academy of
Medicine (NAM)12 to improve guideline quality;
(4) Case scenarios e development of four case scenarios reflect-
ing persons with hand, hip and knee OA considering the
inclusion of comorbidities and different stages of disease
management in order to represent common clinical
situations
(5) Algorithms e development of management algorithms for
each case scenario applying the evidence-based recom-
mendations and the expertise of the panel consensus.Participants
OA panel
We established a comprehensive panel in order to cover
multidisciplinary and transcultural aspects of OA management
with an international focus. The role of this panel was to appraise
the existing pooled evidence base and develop case scenarios and
their respective algorithms. The panel consisted of 15 health pro-
fessionals in the field of OA (physiotherapists, general practitioners,
rheumatologists and orthopaedists) from 8 countries (Chinese,
Portuguese, Swedish and predominantly English speaking) across
different continents (America, Oceania, Europe and Asia). For
further details, including conflicts of interest see Appendix.
Systematic review panel
A subset of the OA panel (AG, AN, JJ, KA and YG) corresponded to
the previous authors of a comprehensive systematic review on
CPGsfor OA management8. The role of this panel was to provide a
critical appraisal of existing treatment guidelines through the up-
date of their previous systematic review by including the most
recent guidelines and respective recommendations.
Trustworthy guidelines assessors
The 16 guidelines were assessed regarding all the criteria and
sub-criteria proposed by the NAM for developing trustworthy
CPGs12. The evaluationwas made by two assessors (SM and TL). DH
acted as moderator in case of disagreement between the assessors.
Public involvement
Two people with knee OA fromAustralia were involved in giving
feedback throughout the process. They participated in the case
scenario formulation, algorithm construction and manuscript
development. All comments were considered and incorporated.
The participants approved the final version of this manuscript and
agreed with its content. All the communications were made via in
person meeting or email.
Systematic review update
The design of the systematic review was developed using the
guidelines of the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses (PRISMA). The PRISMA statement includes a 27-
item checklist for use as a basis for reporting systematic reviews13.
The methodology used here was consistent with the previous work
and is presented as supplementary material. A protocol was not
registered for this review.
Our goal was to update the findings of a previous comprehen-
sive systematic review on CPGs for OA management. Our search
time frame was restricted to January 1st, 2013 to October 1st 2014
to overlap the search of this previous comprehensive review, which
investigated this topic from January 1st 2000 to April 1st 20138. We
searched Medline and the Agency for Healthcare Research &
Quality (AHRQ) Guidelines Clearinghouse using the keywords
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differed from the previous review in order to create a more sensi-
tive search given the short time frame between reviews.
The overall quality of each included guideline was assessed
using the AGREE II instrument (Appraisal of Guidelines for Research
and Evaluation, 2nd edition; www.agreetrust.org). Since the
methodological approach to the updates to previous guidelines did
not change, the scores from the previous versions weremaintained.
Trustworthy guidelines assessment
In March 2011, the NAM established standards for developing
Trustworthy CPGs, in order to examine the quality and trustwor-
thiness of CPGs and how they can be improved to enhance
healthcare quality and patient outcomes12. The NAM standards
include eight criteria items: establishing transparency, manage-
ment of conflict of interest, guideline development group compo-
sition, clinical practice guidelineesystematic review intersection,
establishing evidence foundations for and rating strength of rec-
ommendations, articulation of recommendations, external review
and updating.
The guidelines used in the updated systematic review were
assessed regarding all the criteria and sub-criteria. The evaluation
was conducted by two assessors (SM and SL). In the first meeting, a
table with the NAM standards and the electronic copy of the
guidelines were provided. After both assessors independently
evaluated the compliance of all guidelines to NAM criteria and
completed the table, a second meeting was scheduled in order to
verify disagreements. All conflicting answers were discussed until a
consensus was reached between the two assessors. The remaining
conflicting answers were discussed with a moderator (DH) at a
third meeting in order to produce a final consensus. After this
meeting, valid answers for trustworthy CPG were established.
Case scenarios
The OA panel produced four case scenarios for the most affected
joints: hand (1), knee (2) and hip OA (1). Aspects like symptoms,
comorbidities and previous treatment response were included in
the scenario in order to be consistent with what occurs in clinical
practice. DH developed the first draft. All authors and the two
consumers with OA provided feedback through email over four
rounds and they discussed all issues until consensus was reached.
DH produced the final version.
Algorithms
The algorithm development consisted of four steps. First, we
only selected the recommendations that were consistent across the
guidelines, in other words, we excluded controversial recommen-
dations (i.e., a recommendation advised by one guideline and
advised against by another). To do this we extracted the results of
the updated systematic review and created a list of homogeneous
recommendations.
Second, with the recommendations’ list in hand we selected the
appropriated treatment options for each scenario, considering the
comorbidities and treatment contra-indications.
The third step was the review and feedback process through
email, inwhich we collected and incorporated all suggestions of co-
authors. The OA panel commented on the treatment options and
structure of the algorithms. The group discussed all aspects of
discordance until a consensus was reached, thus the algorithms
were developed using guideline consistency plus expert consensus.
The drafts of each algorithmwere presented to the consumers withOA for feedback and their comments incorporated. DH resolved the
discrepancies and the OA panel approved the final version.
The last step was the design elaboration. The arrangement of the
algorithm was strategically created to facilitate clinical interpreta-
tion. We organised the algorithm structuring the non-
pharmacological and pharmacological interventions in parallel
and surgical options at the bottom since optimal management for
OA requires a combination of conservative non-drug and drug
treatments, with surgery reserved for severe clinical disease with
structural changes17. The intention is to encourage clinicians to
offer first non-invasive interventions always cognisant of symptom
severity and the level of disability of the patient. Clinical practice




After duplicate citations were removed, we screened 101 unique
citations (n ¼ 84 Medline and n ¼ 17 AHRQ) along with the 16 ci-
tations included from the previous review. Full-text review
occurred for 22 manuscripts. Reasons for exclusion of a guideline
after full-text review were: (1) not meeting inclusion criteria
(guideline was not OA-specific [n ¼ 1]15 or (2) a guideline was
outdated by a more recently available update or revised version
[n ¼ 5]16e20. After screening and full text review, we included a
total of 16 articles describing guidelines for OA management
(Fig. 1). The majority of the included articles were consistent with
the previous review (n¼ 15) with two updates (MQIC21 and NICE4),
two revisions (EULAR Hip and Knee5 and OARSI Knee2) and one
additionally identified guideline (Italian Society for Rheuma-
tology22). Five were from the United States1,3,21,23,24 one from
Canada25, eight from Europe4,5,22,26e30 one from Asia31, and one
multinational2. Most recommendations were directed toward
doctors and allied health professionals, and most had multi-
disciplinary input from general practitioners, rheumatologists, or-
thopaedic surgeons, and physiotherapists. Also, a few guidelines
received feedback from patient representatives. The various
grading scales used by the individual societies for their recom-
mendations are summarized in Table 1 (supplementary material).
Agree II
Scaled AGREE II scores were derived from the two independent
reviewers' scores as a percentage of the maximum possible score.
The six domain scores are listed separately. The OARSI guidelines
scored highest on the overall assessment (75%), followed by the
AAOS, ACR, MOVE, and NICE guidelines (all 67%). The highest
domain scores were for scope and purpose (description of overall
objectives, health questions covered, and target population) and
rigor of development (use of systematic methods, clear criteria for
study selection, strengths and limitations of evidence described,
methods of formulating recommendations described, risks and
benefits considered, clear link between recommendation and
supporting evidence, external review, and procedure for updates).
The lowest domain scores were for applicability. This domain in-
cludes items about facilitators and barriers to guideline use,
practical advice regarding guideline implementation, resource
implications, and monitoring/auditing criteria, which were not
often included in the OA guidelines. Several guidelines also did
not adequately discuss issues related to editorial independence.
The summary of recommendations regarding non-
pharmacological interventions can be found in the supplemen-
tary material as Table 2 (education and self-management), Table 3
(exercise and weight loss), Table 4 (assistive devices), Table 5
Fig. 1. Flow diagram for study inclusion.
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terventions) and Table 7 (pharmacological recommendations).
Trustworthy guidelines assessment
All CPGs detailed the development process; however, informa-
tion regarding the funding source was missing from some. Ac-
cording to NAM standards, the management of Conflicts of Interest
(COI) needs to be performed prior to selection of the Guideline
Development Group (GDG), and whenever possible the GDG chair
should not have a COI. However, there was only one guideline
(AAOS) which completely followed these criteria. Other guidelines
presented the authors' COI but included no information about
whether COI were declared prior to formation of the GDG.
The GDGs were frequently composed of a multidisciplinary
group of experts; however, only a few included patient represen-
tatives or advocates in the development process. Strategies and
incentives to increase the effective participation of patient repre-
sentatives were only used by two GDGs (OARSI and EULAR 2013).Most CPGs were based on systematic reviews, but did not inform
whether the articles met the standards set by the NAM's Commit-
tee, and no guideline produced their own systematic review.
Regarding the recommendations, most of the CPGs established
an evidence foundation, rated evidence strength and the majority
articulated them in a standardized form. Only a few CPGs had an
external and confidential review process and provided the oppor-
tunity for the general public for comment on the draft version prior
to final guideline release. The updating process was poorly docu-
mented or not presented in the majority of CPGs. All guidelines
should document the proposed date and conditions for future re-
view, and regularly monitor the literature base to identify the
emergence of new relevant evidence that could potentially affect
the validity of the CPG.
Algorithm development
The algorithm was developed for each case scenario consis-
tent with the evidence from the consensus recommendations
Case Scenario 1. Hand. An overweight sedentary 60 year old female with symptomatic hand OA presents to her primary care provider for treatment. She has a past history of upper
GI problems and depression. She has had pain in several finger joints including the base of thumb for several months. At this point she has not begun any formal medical treatment
for this problem but has tried heat and over the counter and topical NSAID treatments.
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Case Scenario 2. Hip. A 56 year old male with symptomatic hip OA presents to his primary care provider for treatment. He has angina currently well controlled on medication and
chronic kidney disease (GFR ~30 mls/minute). He is normal weight and experiences pain over the lateral aspect of his hip on movement with hip internal rotation limited to 5 with
pain. He has not experienced any benefit from intermittent dosing of over the counter (OTC) acetaminophen.
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Case Scenario 3. Knee 1. An obese 55 year old sedentary female with symptomatic knee OA presents to her primary care provider for treatment. She has depression, sleep apnoea
and hypertension currently well controlled on medication and has previously had a peptic ulcer. She experiences pain in and around one knee (including pain in PF joint) and has
not had an adequate response to either intermittent dosing of OTC acetaminophen, OTC NSAIDs, or OTC nutritional supplements (e.g., chondroitin sulfate, glucosamine). She has
involvement in both the medial tibiofemoral and patellofemoral compartments.
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Case Scenario 4. Knee 2. An overweight 48 year old male with symptomatic knee OA (and mild hip OA) presents to his primary care provider for treatment 15 years following a
lateral meniscectomy. He has no cardiovascular comorbidities but does have a history of prior peptic ulcer. He works in the building industry in a physically demanding role. He
experiences pain in and around the knee and has not had an adequate response to either intermittent dosing of OTC acetaminophen, NSAIDs, or nutritional supplements (e.g.,
chondroitin sulfate, glucosamine). Opioid drugs whilst helpful made him nauseated and drowsy. He has radiological involvement in the lateral tibiofemoral compartment and
marked quadriceps weakness.
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improve clarity for the general reader we provided the criteria
for which we would make a diagnosis of OA. Therefore, for each
case, we added the common signs and symptoms based on Map
of Medicine Healthguides32. We also included a warning box to
check for comorbidities with examples of the most frequent
conditions.
As suggested by the OA panel, the algorithm includes more
conservative or less costly treatment approaches prior to more
invasive, expensive or potentially harmful interventions, such as:
(A) Referral to physiotherapist or occupational therapist: the first
approach should be group activity/exercise programs available at
the patient's community or home exercise program and the referral
criteria for therapy should be “if in the clinicians' judgment the
patient is weak, stiff or has other functional deficits”. (B) Assistive
devices and orthoses with the condition “if ADL is impaired”. (C)
Braces and footwear/insoles only “if malalignment”. (D) Invasive
interventions like intra-articular injections with the criteria “If not
effective (prior pharmacological treatment), consider referral to
specialist for invasive treatment options”. (E) Opioid therapy, “if the
patient has severe and disabling pain, consider opioid for short
term use only and insist on non-pharmacological interventions”
and (F) Surgery “if disabling symptoms and if already exhausted all
other options including pharmacological and non-pharmacological
interventions”.
For patients with concurrent conditions such as upper GI
problems, peptic ulcer and chronic kidney disease we excluded oral
non selective nonsteroidal anti-inflammatory drug (NSAID), except
in the case 1 where the patient has a past history of upper GI
problems; for this case we consider NSAID or cyclooxygenase-2
inhibitors (COX-2), both added to a proton-pump inhibitors (PPI)
for gastroprotection in case of failure of acetaminophen treatment.
For others, we recommended continued intermittent acetamino-
phen and topical NSAIDs. Depending on effect and after consider-
ation of potential for harm we recommended considering a
COX2 þPPI for other cases where there is concern over GI toxicity.
We excluded topical NSAID for the hip case since we believed the
drug is incapable of reaching the joint with therapeutic effect. We
also excluded drugs previously used by patients that were not
effective for them (e.g., In the hip-case 2 algorithm we excluded
acetaminophen from the algorithm since the patient reported not
experiencing any benefit from intermittent dosing of over the
counter acetaminophen).
Other important input from the panel was the suggestion, based
on clinical judgment, to include a post-operative physical therapy
program. This was not explicitly included in the guidelines but was
considered essential by the panel, since the treatment and follow-
up of patients does not finish immediately after surgery.
The guidelines recommended psychological interventions for
patients with hip and knee OA. We gave an example of an inter-
vention (cognitive behavioural therapy) and the specific purpose
of this kind of intervention: “for assistance with pain coping or
psychological symptoms if appropriate”. The recommendation
from guidelines “weight loss, if overweight” was slightly adapted
and instead of referring to a dietician, we included instruction for
the patient to join a weight loss program available in community,
since not all patients may have access to dieticians. This type of
program focuses on nutrition and physical activity education. The
panel considered that some recommendations were not specific
and clear enough to be used in the algorithm, such as lifestyle
changes, joint protection, and regular contact to promote self-
care.
It is worth noting that for the recommendations used during
the construction of the algorithm for the hip case, weextrapolated the evidence from knee OA management. The
reason for this is that guidelines related to hip OA are usually
produced in combination with knee OA and studies involving hip
OA only are scarce.Discussion
The purpose of this exercise were: (i) to harmonize the recent
guidelines, searching for common ground among the recom-
mended treatment options for OA and (ii) to develop user-friendly
management algorithms for common case scenarios as a method to
discuss, prioritise and put into a complex setting/context the
different individual recommendations, aiming to facilitate the
translation of evidence-based recommendations into practice. We
updated a systematic review and based on recent evidence-based
recommendations we built an algorithm to address each case
scenario.
Regarding the trustworthy guidelines assessment, future CPGs
should follow the standards proposed by the NAM in order to
ensure the quality of the processes supporting development of
CPGs. Our analysis suggests that many guidelines still present a lack
of transparency, particularly with regards to the management of
conflict of interest, external review process and information about
planned future updates. It is important to note that all the guide-
lines used in this paper were not specifically designed to achieve
the NAM standards, thus we cannot apply to them the rigour of how
the criteria were addressed. The key message is to incentivize
future guidelines to address these standards in order to improve
quality and transparency.
In the updated systematic review, a limited number of addi-
tional articles were identified to those included in the previous
review by Nelson and colleagues8. Two guidelines were updated,
two reviewed and one new guideline introduced. Once again, it is
evident that the majority of interventions are consistently recom-
mended across guidelines, such as education, exercise, and weight
loss. Some were still conflicting like acupuncture, glucosamine/
chondroitin supplementation and intra-articular hyaluronans. The
main reason highlighted in guidelines for disagreements is the lack
of efficacy of these interventions. The focus of guideline dissemi-
nation should be for interventions where there is consistent strong
and reliable clinical support. Our results are broadly consistent with
recently published systematic appraisals of guidelines in the
literature33.
Due to their general consistency, most of the recommendations
can be applied in clinical practice. However, at present there is
insufficient uptake6,7. Consistent with this concern, our results
demonstrate that the lowest domain scores in the AGREE II were for
applicability of guidelines. This domain includes important points
like discussion of facilitators and barriers to application, provision
of advice for practical use, consideration of resource implications,
and monitoring/auditing criteria. Poor results in AGREE II were also
shown in a 2014 systematic review of non-pharmacological man-
agement of OA34. This lack of focus on the applicability of a CPG
seems contradictory to the primary purpose of the guideline in
guiding and improving clinical practice. Fortunately, the most
recent guidelines seem to better address the domains of the AGREE
II8. With this in mind, this algorithm exercise is an example of
practical use of recommendations in common clinical scenarios to
facilitate the practical use of guidelines. In addition, the algorithms
establish some criteria to consider for the triage or judicious use of
some interventions. Future guidelines could use this methodology
in order to facilitate the implementation of recommendations. It is
important to note that the AGREE scores reported are based upon
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differing opinions.
While people with severe OA symptoms may warrant a com-
bination of treatment modalities, e.g., exercise, pharmacological
and potentially surgical interventions, people with mild to mod-
erate OA symptoms should consider non pharmacologic manage-
ment in the first instance35,36. Guidelines routinely advocate their
use but studies suggest that their use in clinical practice is sub-
optimal37. Our hope is that this study provides guidance on how to
extract the information present in guidelines in a logical manner
and consequently improve the management of patients with OA.
The algorithm is also a visualization of what is often times overly
comprehensive guidelines with extensive text that may limit
interpretation and ready dissemination.
There is a great need for further work in the rational allocation
of health resources which besides the clinical judgement must
take into account health economic aspects. Therefore, it is
important to establish the best way of combining the current
evidence on the treatment of OA, facilitating this way the con-
struction of an efficient treatment plan and improving the cost-
effectiveness of these interventions. With this in mind, the Eu-
ropean Society for Clinical and Economic Aspects of Osteoporosis
and Osteoarthritis (ESCEO) group proposed a set of disease-
specific recommendations on the conduct and reporting of eco-
nomic evaluations in OA that could help the standardization and
comparability of studies that evaluate therapeutic strategies of OA
in terms of costs and effectiveness38.
In this paper, we aimed to rationalise the recommended treat-
ment options considering an ideal management. We are aware that
some options indicated are not available for the entire international
population, however we considered it important to present what
would be the best treatment scenario for each case. We believe that
clinicians should opt for the non-pharmacological options prior to
the pharmacological pathway; however we know that in the clin-
ical practice this is not the reality. Thus, we chose to organise both
treatments in parallel but here we state this hierarchy would
represent a better sequence.
In addition, it is important to note that some interventions must
be better studied in order to reduce the number of contradictory
and inconclusive recommendations among the guidelines. As
example, for the hand OA case, due to inconsistency within the
guidelines we did not recommend acetaminophen and intra-
articular corticosteroid injections. In our case, we solved the con-
flicts with help of the OA panel. A recent systematic review and
meta-analysis39 showed that paracetamol provides minimal short
term benefit for people with OA. Thus, we decided to offer it as one
of the last options on the algorithms. Future guidelines should
include this important finding since paracetamol is often the first
option among the pharmacological options.
Another significant point is that we lack full understanding of
whowill get themost benefit and least harm for each treatment. On
the algorithms we intentionally left the surgical options at the end
with awarning that all the other optionsmust be already exhausted
before offering the option of surgery. The reason for this is that in
spite of universal recommendations for total joint replacement
(TJR) in severe cases of OA unresponsive to other therapies, there is
insufficient high-quality evidence to support (or quantify) its
benefit over the other treatments and there are certainly associated
adverse events.
Information that is not presented in any guideline is the follow-
up period after a joint replacement. We considered it relevant to
include this step in all algorithms as: “individualised exercise
program aiming for personalized goals for strength, ROM andfunction regarding the replaced joint and other joints at risk”. We
believe this is a crucial step in the rehabilitation process and future
guidelines should pay more attention to it. Furthermore, we pro-
vided in each algorithm a boxwith clinical signs and symptoms and
another with comorbidities check-list. We expect with this to
encourage clinicians to diagnose OA based on clinical findings
rather than radiological and always consider the comorbidities that
the patient might have in order to carefully plan the treatment
strategy.
There are some important limitations of this work that warrant
mention. Firstly, these algorithms are the work of a select group of
health professional researchers and do not necessarily reflect the
opinions of the organizations that they come from, nor those of
others in the field of OA. Another limitation is that only one general
practitioner was involved, whereas they are the primary end users.
Whilst we appraised and disclosed conflicts of interest, indepen-
dence from competing interests can never be guaranteed and this
paper should be appraisedwith that caveat inmind. In addition, not
all contexts globally are consistent with regards to access to certain
interventions, resource implications and barriers to care, so some of
the algorithms/interventions may not be optimal or applicable for
certain countries. Finally, only guidelines published in English were
reviewed, leading to a potential publication bias. We planned to
update this paper in three years after it is published or when new
evidence suggests the need for modification of clinically important
recommendations.
Conclusion
In summary, the relative consensus within the guidelines sug-
gests that rather than a lack of quality, there is a failure in the
application of the recommendations in clinical practice. The algo-
rithms proposed are examples of how to discuss, prioritise and put
into a complex setting/context the different individual recom-
mendations, aiming to facilitate the translation of evidence-based
recommendations into practice.
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